Om All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier
Since 2020 this podcast is an invaluable resource for health care professionals, and anyone interested in learning more about urticaria. In the first 97 episodes, Prof. Marcus Maurer († 31.07.2024) is joined by colleagues for in-depth discussions on the latest research and opinion on the pathogenesis and treatment of urticaria. Prof. Torsten Zuberbier has taken on this role. All opinions expressed are those of the faculty. This content should not be taken as medical advice and is for informational purposes only. Learn more about the network and its activities here: https://ucare-network.com/
📻 Siste episoder av All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier
Her er de nyeste episodene tilgjengelige via RSS-feeden:
Laster episoder...
📱 Slik abonnerer du på All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier
In this short, conference-based episode, Professor Torsten Zuberbier, President of Global Allergy and Asthma Excellence Network, speaks with Professor Kiran Godse from Mumbai, India, directly from the UCARE Urticaria Conference, sharing the latest breakthroughs in urticaria research and treatment. The discuss: 🔹 What are the most important new developments in urticaria therapy? 🔹 How do BTK inhibitors change the way chronic urticaria is treated? 🔹 Why can these new drugs work in both autoimmune and autoallergic urticaria? 🔹 How can digital tools like the CRUSE App support patients and physicians? Professor Godse highlights the rapid progress made over the past year, including the emergence of novel oral therapies that caneffectively control most forms of chronic urticaria. The discussion focuses on BTK inhibitors, which act inside the mast cell to block histamine release at its source, offering a new, convenient tablet-based treatment option. In addition, the episode emphasizes the growing role of digital patient tools, such as the CRUSE App, which help patients monitor disease activity and support personalized treatment decisions worldwide.Key Learnings from the Episode:Chronic urticaria consists of autoallergic and autoimmune subtypes, both of which can be targeted by new BTK inhibitors. BTK inhibitors block mast-cell signaling inside the cell, preventing histamine release and reducing symptoms effectively. New oral therapies offer once- or twice-daily tablet options, improving convenience and adherence for patients. Several new urticaria treatments have been approved globally, with wider availability expected soon. The CRUSE App enables patients to track disease activity and supports data-driven clinical decisions. Digital tools improve doctor–patient communication and help personalize treatment strategies. Global initiatives like UCARE are transforming urticaria care through research, education, and collaboration. The outlook for urticaria patients is increasingly positive, with more effective and accessible treatments emerging worldwide. Chapters:00:00 Introduction to UCARE Conference01:31 New Developments in Urticaria Treatment03:22 Innovative Apps for Patient Management
Measuring What Matters: PROMs in Urticaria Care (00:19:43)
In this episode of the GA²LEN (Global Allergy and Asthma Excellence Network) Podcast on Everything Urticaria, Professor Torsten Zuberbier talks with Dr. Karsten Weller, a leading expert and developer of patient-reported outcome measures (PROMs), about how these tools are transforming the management of urticaria and angioedema in both research and daily care. The discuss: 🔹 What are PROMs and why are they essential in urticaria management? 🔹 How are they developed and validated scientifically? 🔹 Which tools should clinicians use in everyday practice? 🔹 What does the future hold for digital and app-based patient assessment? Dr. Weller explains how PROMs such as the Urticaria Control Test (UCT) help physicians understand disease control directly from the patient’s perspective. He discusses the scientific process of developing and validating PROMs, the benefits of integrating them into digital tools like the CRUSE App, and how simple, standardized communication enhances care. Together, they explore the future of patient-centered assessment, from wearable technologies to the evolving language of quality-of-life measures. Key Learnings from the Episode:PROMs capture the patient’s own perception of disease activity, control, and quality of life—crucial for fluctuating conditions like urticaria. The Urticaria Control Test (UCT) is a quick, validated 4-question tool recommended for every patient visit. PROM development follows a rigorous process including patient input, expert review, and validation studies. Tools like the Chronic Urticaria QoL Questionnaire (CU-Q2oL) and Angioedema QoL Questionnaire (AE-QoL) add depth when time allows. Digital apps such as the CRUSE App integrate PROMs into daily life and facilitate doctor–patient communication. Despite new technologies, the patient’s direct voice remains irreplaceable in capturing holistic well-being. The language of questionnaires must be periodically reviewed to stay clear and relevant across generations. PROMs promote standardized, efficient, and patient-centered care, empowering better decisions and stronger engagement. Chapters00:00 Introduction to Patient-Reported Outcome Measures (PROMs)03:23 The Development Process of PROMs05:57 Practical Application of PROMs in Clinical Practice08:40 The Future of Digital Tools in Patient Care11:28 Language and Communication in Patient-Reported Outcomes14:10 Final Thoughts and Conclusion
Why Do Hives Look the Way They Do? (00:21:25)
In this episode of the GA²LEN (Global Allergy and Asthma Excellence Network) Podcast on Everything Urticaria, Professor Torsten Zuberbier speaks with Professor Michihiro Hide from Hiroshima, Japan — a pioneer in urticaria research — about an unexpected connection between dermatology and mathematics. The discuss: 🔹 Why do urticaria wheals form distinct shapes — round, annular, or geographic? 🔹 What controls how long a wheal lasts before fading? 🔹 Can mathematical formulas help explain the biology of hives? 🔹 What could this mean for diagnosis and treatment in the future? Professor Hide shares how a collaboration with a mathematician led to the creation of a computational model that simulates wheal formation in silico, revealing five recurring urticaria patterns that correspond to clinical types such as cholinergic or chronic spontaneous urticaria. Together, the two professors explore how mast cells, basophils, endothelial cells, and coagulation factors interact through feedback loops to create (and stop) a wheal — and how this model could reshape our understanding of urticaria’s pathophysiology and treatment. Key Learnings from the Episode Urticaria’s shapes and lifespans can be mathematically modeled using Turing-inspired reaction-diffusion formulas. Five recurring patterns of wheals emerged from simulations, mirroring real-world urticaria morphology. Basophil-driven small dots (e.g., cholinergic urticaria) differ mechanistically from mast-cell-driven geographic wheals. Wheals persist longer than histamine-only reactions, implying sustained mast-cell activation. Urticaria develops through three stages — initiation, expansion, and resolution — governed by positive and negative feedback. Understanding the inhibitory phase that stops mast-cell activation is a key future research frontier. Mathematical modeling could help visualize and predict disease activity, opening paths for personalized therapy. Collaboration between clinicians and mathematicians may lead to a new diagnostic and research paradigm in chronic urticaria. Chapters 00:00 Introduction to Urticaria Research 02:03 Exploring the Mechanisms of Urticaria 06:25 Mathematical Approaches to Urticaria 10:30 Patterns and Predictions in Urticaria 15:37 Understanding Treatment Responses 19:07 Future Directions in Urticaria Research Press releasehttps://www.eurekalert.org/news-releases/1009793 References1. Seirin-Lee S, et al. A single reaction-diffusion equation for. the multifarious eruptions of urticaria. PLOS Computational Biology. 2020;16(1):e10075902. Seirin-LeeS, et al. Mathematical-based morphological classification of skin eruptions corresponding to the pathophysiological state of chronic spontaneous urticaria.Communications Medicine. 2023;3(1):171.3. Seirin-Lee S, et al. Pathophysiological Mechanisms of the Onset, Development, and Disappearance Phases of Skin Eruptions in Chronic Spontaneous Urticaria, Bulletin of Mathematical Biology. 2025; 87, 1Michihiro Hide has receivedlecture and/or consultation fees from Japan Tobacco, Kaken, Kyorin, KyowaKirin, Meiji Seiyaku, Mitsubishi Tanabe, Nippon Zoki, Novartis, Sanofi, Taiho,Teikoku and Yuhan.Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Feedback form: ATU: https://forms.office.com/e/m6a2uEdsUH
UDAY & New Guidelines: Empowering Patients Worldwide (00:17:52)
In this episode, Prof. Torsten Zuberbier (Global Allergy and Asthma Excellence Network President) welcomes Prof. Petra Staubach, urticaria expert from Germany, to talk about Urticaria Day (UDAY) — held each year on October 1st — and why awareness is just as important as science. They discuss: 🔹 Why do we need a dedicated awareness day for urticaria? 🔹 What is the true burden of urticaria on patients and families? 🔹 How can physicians and patients improve communication and advocacy? 🔹 What do the new 2025 urticaria guidelines mean for treatment worldwide? Together, they highlight the unmet needs of urticaria patients, the role of patient organizations, and the importance of empowering patients to speak openly about their burden. The discussion also previews the new treatment options in the 2025 guideline, including biosimilars of omalizumab, dupilumab, and remibrutinib. Join us for this inspiring episode on why urticaria is a serious disease that deserves global awareness — and how new therapies and guidelines are changing the future. Key Learnings from the Episode:Urticaria Day (UDAY) has been celebrated since 2014 to raise global awareness about the seriousness of urticaria. Despite perceptions of being “just hives,” urticaria causes major quality-of-life impairment: sleep disruption, depression, social isolation, and stigma. 84% of patients feel embarrassed to be seen with wheals or angioedema. Urticaria affects people of all ages, from children to the elderly, with equal burden. Physicians often underestimate disease control compared to patient perception, creating a communication gap. Patient honesty and empowerment are crucial: patients should describe the real impact of disease to their doctors. Patient organizations help bridge gaps, provide support, and increase awareness globally — but many countries still lack them. The 2025 urticaria guideline will emphasize: Early up-dosing of antihistamines (don’t wait months if ineffective). Omalizumab remains the global standard, now also with biosimilars. Dupilumab (already used in asthma/atopic dermatitis) and Remibrutinib (oral BTK inhibitor) enter the treatment landscape. Flexibility: co-administration with cyclosporine, consideration of costs, and tailoring to patient burden. The key message: Stay flexible, treat early, and adapt care to the patient’s real needs. Awareness & advocacy matter: urticaria’s burden is as high as ischemic heart disease — it must be taken seriously by society and healthcare systems. Chapters00:00 Introduction to Urticaria Awareness02:32 The Importance of Urticaria Day05:16 Understanding the Burden of Urticaria07:58 Communication Between Patients and Physicians10:59 Future Treatment Options for Urticaria14:05 Conclusion and Call to ActionDo you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
Living with SD: from Triggers to Future Therapies (00:24:05)
In this episode, Sophia Neisinger welcomes Dr. Melba Muñoz, head of the Chronic Inducible Urticaria Program in Berlin, to discuss symptomatic dermographism (SD), the most common form of inducible urticaria. They discuss: 🔹 What exactly is symptomatic dermographism, and why is it so burdensome for patients? 🔹 How common is SD, and what did the latest international prevalence study reveal? 🔹 How can tools like the FricTest help diagnose and assess SD? 🔹 Which treatments are available today—and which exciting therapies are on the horizon? Dr. Muñoz shares insights on the challenges SD patients face in daily life, the importance of proper diagnosis, and why new therapies in clinical trials may soon change the landscape of treatment. She also highlights the need for awareness among both physicians and patients to reduce diagnostic delays and improve care. Join us for this engaging conversation on how better diagnostics, treatment options, and awareness can transform the lives of SD patients. Key Learnings from the Episode Definition: Symptomatic dermographism is a form of inducible urticaria where scratching or stroking on the skin leads to wheals, redness, and itch. Prevalence: International data suggest approximately 4% of the population may be affected, making it surprisingly common. Impact: Even daily activities like wearing clothes or combing hair can trigger symptoms, causing significant quality-of-life impairment. Diagnosis: The FricTest is a standardized tool to diagnose and measure SD activity, more reliable than ad-hoc methods like using a pen. Overlap: Around 30–40% of SD patients also present with chronic spontaneous urticaria (CSU). Treatment today: Only antihistamines are licensed; omalizumab may be used off-label (or in-label if CSU is present). Future therapies: Anti-KIT antibodies (barzolvolimab, briquilumab), oral KIT inhibitors, and BTK inhibitors (remibrutinib) show great promise. Diagnostic delays: Many SD patients experience long delays, partly due to lack of awareness and the perception that symptoms are "normal." Patient-reported tools: The Urticaria Control Test (UCT) and the new SD-Qual scale are validated instruments for assessing disease control and quality of life. Awareness: Education for general practitioners and patients is key, as many still use antihistamines incorrectly (on demand instead of regularly). Chapters 00:00 Introduction to Symptomatic Demographism 02:53 Understanding Symptomatic Demographism 04:49 Prevalence and Diagnosis of SD 06:54 Diagnostic Tools for SD 09:16 Treatment Options for SD 13:52 Challenges in Diagnosis and Awareness 18:40 Patient-Reported Outcomes and Future Directions Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
Urticaria in Children: Diagnosis, Triggers & Treatment (00:19:35)
In this episode, Prof. Torsten Zuberbier welcomes Dr. Larissa Brandão, pediatric allergist from the Federal University of São Paulo, Brazil, to talk about chronic urticaria in children — a condition that is often misunderstood and underdiagnosed. They discuss: 🔹 When does chronic urticaria typically begin in kids? 🔹 What role do infections or allergens, play? 🔹 Which treatments are available in public healthcare? 🔹 How do cold urticaria and cholinergic urticaria show up in warm climates?Dr. Brandão shares her clinical experience from Brazil, where many children with chronic urticaria also suffer from comorbidities like asthma and allergic rhinitis. She explains how treatment responses differ from adults and discusses the impact of restricted access to second-generation antihistamines.Join us for a practical and global look at what it takes to recognize, treat, and support children with chronic urticaria — especially in resource-limited settings. Key Learnings from the Episode Chronic urticaria in children typically begins around age 7–8, with chronic spontaneous urticaria (CSU) being the most common subtype. In Brazil is the most common chronic inducible form; cold urticaria and cholinergic urticaria are also present but less frequent. Cold triggers in Brazil include ice cream, cold drinks, pools, and beaches — not ambient winter weather. Pediatric CSU patients often have comorbid atopic conditions, especially asthma and allergic rhinitis. Children tend to respond better than adults to standard or up-dosed second-generation antihistamines, but fatigue can be a common side effect. Loratadine is the only antihistamine widely available through Brazil’s public health system; desloratadine, bilastine, or fexofenadine are often unaffordable. Liver function monitoring is used for kids on high-dose loratadine. Omalizumab is rarely needed, but effective in more severe pediatric cases — especially those with comorbid asthma. Dupilumab is now licensed in Brazil for CSU in children aged 12+, and early reports show benefits for patients with both asthma and urticaria. Pseudoallergen-triggered symptoms (e.g. from candy, dyes, preservatives) are observed, and short-term elimination diets are used diagnostically. Cold urticaria can cause anaphylaxis, especially in pools — and adrenaline auto-injectors are recommended for high-risk children. Counseling on safety, including family education about temperature triggers, is essential for cold urticaria management. Brazilian UCARE centers use social media and in-clinic education to raise awareness and prepare for Urticaria Day (October 1) each year. Chapters00:00 Introduction to Urticaria in Children01:46 Understanding Chronic Urticaria in Children03:33 Infections and Chronic Urticaria05:13 Allergic Comorbidities in Children06:27 Treatment Algorithms for Chronic Urticaria08:32 Dietary Influences on Urticaria12:09 Cold Urticaria and Safety Concerns15:13 Advancements in Urticaria Treatment17:30 Advocacy and Awareness for UrticariaDo you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
In this episode, Prof. Torsten Zuberbier welcomes Prof. Gil Yosipovitch, world-renowned itch researcher and dermatologist at the University of Miami, for an in-depth discussion on the science of itch in urticaria, and why histamine isn’t the full story. They discuss: 🔹 Why do antihistamines fail in up to 40% of urticaria patients? 🔹 What is MRGPRX2, and why is it such a promising target for future treatments? 🔹 How do pain and itch differ neurologically — and why is itch harder to ignore? 🔹 What role do topical steroids, JAK inhibitors, and GABAergic drugs play? Prof. Yosipovitch shares clinical and research insights on chronic itch mechanisms, highlighting how mast cells, nerves, cytokines, and ion channels interact to drive symptoms. The episode also explores why scratching can feel pleasurable, what makes urticaria itch unique, and how new therapies could revolutionize care. Join us for a cutting-edge conversation on the future of urticaria treatment — and why individualized care is the most powerful approach of all. Key Learnings from the Episode Chronic urticaria itch is not purely histaminergic — up to 40% of patients don’t respond to antihistamines, indicating other mechanisms. MRGPRX2 is a key non-histaminergic itch receptor found on mast cells and possibly nerve fibers — and is overexpressed in many itch disorders. Scratching itch activates pleasure centers in the brain, but urticaria patients scratch less deeply than those with atopic dermatitis. Cold and heat don’t always inhibit itch — responses vary across diseases and individuals, involving channels like TRPM8. Steroids and JAK inhibitors modulate both histaminergic and non-histaminergic itch pathways. Long-term steroid use is still widespread, especially in the US — but leads to serious comorbidities.Gabapentin and SNRIs like mirtazapine are valid add-on options in selected chronic itch patients. New biologics and mast cell-targeting drugs (like CKIT inhibitors) are on the horizon and may transform treatment. Each patient is unique — clinicians must move beyond dogma and adjust treatments to the individual, not just the guideline. Chapters00:00 Understanding Itch: The Science Behind Chronic Pruritus03:02 The Role of MRGPRX2 in Itch Mechanisms05:53 Pain vs. Itch: Exploring the Neural Pathways09:03 Individual Patient Experiences: The Complexity of Itch11:48 Treatment Approaches: Antihistamines and Beyond15:11 Emerging Therapies: The Future of Itch ManagementDo you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
Females, Pregnancy & Chronic Urticaria: What Doctors Should Know (00:18:51)
In this episode, Dr. Sophia Neisinger welcomes Prof. Emek Kocatürk, leading urticaria researcher and UCARE expert from Istanbul, to explore the gender-specific aspects of chronic urticaria, with a special focus on pregnancy. They discuss: 🔹 Why do more women than men suffer from chronic urticaria? 🔹 How does pregnancy affect urticaria symptoms and treatment response? 🔹 What medications are safe during pregnancy and breastfeeding? 🔹 How should physicians approach treatment decisions with female patients? Prof. Kocatürk shares key insights from the PREG-CU study, involving over 300 pregnant CSU patients, and explains why half of them improve during pregnancy. She outlines practical treatment guidelines for antihistamines and omalizumab use during pregnancy and breastfeeding, discusses estrogen’s inflammatory role, and gives tips for shared decision-making in clinical care. Join us for an important and empowering episode that sheds light on female-specific urticaria challenges and how to manage them with evidence-based confidence.Key Learnings from the Episode 70% of CSU patients are female, pointing to hormonal and autoimmune factors in disease susceptibility. Female CSU patients suffer more: more angioedema, systemic symptoms, worse disease control, and more comorbidities like asthma, thyroid disease, and depression. The PREG-CU study showed that 50% of CSU patients improve during pregnancy, offering hope to women planning to conceive. Exacerbations during pregnancy are common and linked to worse pregnancy outcomes if untreated. Antihistamines (especially cetirizine, loratadine) are safe in pregnancy; second-generation agents are preferred. Omalizumab is safe in pregnancy and lactation, particularly starting in the second trimester. Antihistamines can be safely continued and even up-dosed during breastfeeding. Keeping CSU under control during and after pregnancy is essential for maternal well-being and newborn bonding. Shared decision-making and good counseling reduce fear and improve patient experience. Digital tools, registries like CURE and CARE, and collaborative research are key to improving care for women with urticaria. Chapters 00:00 Understanding Chronic Urticaria: A Female Predominance 06:20 Pregnancy and Chronic Urticaria: What to Expect 11:36 Managing Urticaria During Pregnancy and Lactation 17:18 Fun Facts and Closing Thoughts Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
The spectrum of cold urticaria (00:21:05)
In this episode, Prof. Torsten Zuberbier calls up Dr. Hanna Bonnekoh, dermatologist and researcher at Charité Berlin, to dive into the complexities of cold-induced urticaria—particularly rare and familial forms that challenge current diagnostics and treatments. They discuss: 🔹 What makes wind-induced cold urticaria so difficult to diagnose? 🔹 How can physicians distinguish between histamine- and IL-1-mediated disease? 🔹 What role do biologics like omalizumab and dupilumab play in treatment? 🔹 Why are IL-1 blockers crucial in autoinflammatory syndromes like Muckle-Wells-syndrome? Dr. Bonnekoh shares her clinical perspective on diagnostic tools like the TempTest, the pathophysiology behind cold urticaria variants, and how novel therapies like anti-CKIT antibodies are shaping the future of care. She also emphasizes the importance of family history, wheal morphology, and systemic symptoms when evaluating patients with atypical urticaria. Join us for a deep dive into cold urticaria phenotypes, treatment strategies, and the call for more research and global registry data to support patients worldwide. Key Learnings from the Episode Cold urticaria includes rare phenotypes, such as wind-induced and familial forms, often undetectable by standard tests. The TempTest is useful for threshold diagnosis, but not all cold urticaria types respond. Histamine-mediated urticaria may respond to antihistamines or omalizumab, while IL-1-mediated types (e.g., Muckle-Wells) require immunomodulatory therapy. IL-1 plays a key role in autoinflammation; identifying its overproduction is crucial in diagnosis. CRP and ESR are easy, accessible lab markers to differentiate urticaria types. New biologics like anti-CKIT antibodies (e.g., barzolvolimab) are promising in depleting mast cells. Wheal appearance, duration, and sensations (itch vs. burn) help guide subtype classification. Cold-induced cholinergic urticaria is an emerging phenotype needing further research. Global registries like CURE are key to improving care for rare urticaria types. Chapters 00:00 Introduction to Cold-Induced Problems 03:29 Understanding Atypical Cold Urticaria 06:23 Treatment Options for Cold Urticaria 09:12 Exploring Rare Forms of Cold Urticaria 11:53 The Role of Interleukin-1 in Cold Urticaria 14:40 Differential Diagnosis in Cold Urticaria 17:15 Research and Future Directions in Cold Urticaria Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
Urticaria Tracking with CRUSE: A Game-Changer for Patients & Research (00:15:44)
In this episode, Prof. Dr. Torsten Zuberbier (GA²LEN) welcomes Dr. Sophia Neisinger to discuss CRUSE, a digital health tool for chronic spontaneous urticaria (CSU). CRUSE is a free, globally available self-evaluation app that helps patients track their symptoms and provides valuable research data to improve urticaria care. They discuss: 📊 How CRUSE helps patients track their CSU symptoms daily. 🔬 How anonymized CRUSE data is shaping global urticaria research. 📢 The importance of continuous data input—even on good days. 💊 Treatment disparities worldwide & the fight against long-term corticosteroid use. 📡 Upcoming developments, including smartwatch & wearable integration. Join us as we explore how CRUSE is making a difference for patients, physicians, and researchers worldwide! Key Learnings from the Episode:CRUSE is a free, validated self-evaluation app for CSU patients, helping track their disease and treatment effectiveness. Daily symptom tracking is crucial, even when patients feel well, to improve research insights. CRUSE data reveals treatment disparities worldwide, with some countries lacking access to second-line treatments. Systemic corticosteroids are still overused, despite their severe side effects, highlighting the need for better awareness and alternative treatments. CRUSE allows patients to share their symptom data with their physicians, improving personalized treatment decisions. The app is continuously evolving, with new features like improved reports and future integration with smartwatches and wearables. CRUSE is expanding globally, with North Macedonia being the next country to adopt the platform. Physicians and researchers can use CRUSE for studies, making it a valuable tool for small-scale trials and real-world data collection. Chapters 00:00 Introduction to CRUISE and Its Purpose 03:18 Data Collection and Patient Engagement 05:47 Global Insights from CRUISE Data 08:52 Future Developments and Enhancements 11:35 Awareness and Advocacy for Urticaria Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
In this episode, Prof. Torsten Zuberbier (Charité Berlin, GA²LEN) welcomes Dr. Stefan Frischbutter, senior researcher at the Institute of Allergy in Berlin, to explore the fascinating world of mast cells and urticaria. They discuss: 🔬 The critical role of mast cells in immune responses and skin conditions like urticaria. 💡 How temperature, autoantibodies, and nerves can trigger mast cell activation. 🦠 Different types of mast cell activation: IgE, IgG autoantibodies & pseudo-allergens. 🧪 New research techniques to study mast cells and identify better treatments. 💊 How eosinophils, neutrophils & T-cells influence chronic urticaria severity. 📢 The latest advances in urticaria treatment and why biopsies could guide therapy. Join us for an insightful discussion on the immune system’s “orchestrators” and how scientific discoveries are shaping the future of urticaria treatment! Key Learnings from the epsiode:Mast cells act as immune response directors, responding to heat, cold, allergens, stress, and autoantibodies. Urticaria has multiple causes, including IgE and IgG autoantibodies, pseudo-allergen receptors (MRGPRX2), and nerve signals. Not all urticaria cases are histamine-driven—other immune cells like eosinophils and neutrophils play a major role. Chronic spontaneous urticaria patients often have autoantibodies targeting mast cells, making treatment challenging. Taking a skin biopsy at the right time (after a wheal disappears) can reveal immune cell involvement and guide personalized treatments. New research techniques, like mast cell activation tests and ex-vivo skin models, help identify triggers and potential treatments. Different immune cells require different treatments, and eosinophil/neutrophil-driven urticaria may need specialized drugs. Exciting future treatments are emerging, and ongoing research will provide better-targeted therapies for urticaria patients. Chapters 00:00 Introduction to Mast Cells and Their Importance 02:50 Understanding Urticaria and Its Triggers 05:55 Mast Cell Activation Mechanisms 08:30 The Role of Other Immune Cells in Urticaria 11:30 Clinical Implications and Biopsy Timing 14:08 Research Advances and Future Directions Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form:ATU: https://forms.office.com/e/m6a2uEdsUH
Episode 104 – Insights from the Global Urticaria Forum (GUF) (00:22:26)
CSU expert Professor Ana Maria Giménez-Arnau joins Professor Torsten Zuberbier to discuss the past, present, and future of treatment for CSU, exploring the current treatment paradigm and new approaches on the horizon that might bring us closer to disease-modifying therapies.Disclosure statement: AGA is or recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Blue -Print, Celldex, Escient Pharmaceuticals, Genentech, GSK, Harmonic Bio, Instituto Carlos III- FEDER, Jaspers, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Noucor, Novartis, Sanofi–Regeneron , Septerna, Servier, Thermo Fisher Scientific, Uriach Pharma.Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATU: https://forms.office.com/e/m6a2uEdsUH
Episode 103 - Solar urticaria (00:15:55)
What steps can be taken to manage solar urticaria? Professor Torsten Zuberbier and Dr Lea Kiefer examine solar urticaria, discussing the role of skin type, management strategies, and treatment methods.Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATU: https://forms.office.com/e/m6a2uEdsUH
Episode 102 - Understanding urticaria: What you need to know (00:20:12)
Professor Torsten Zuberbier welcomes Dr Luis Ensina to discuss essential information for people with urticaria, highlighting the benefits of keeping a diary before medical appointments and how using patient-reported outcome tools can help doctors understand their condition better.Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATU: https://forms.office.com/e/m6a2uEdsUH
Episode 101 - Live from Global Urticaria Forum (00:10:23)
Episode 101 – What were the highlights at Global Urticaria Forum (GUF) 2024? Professor Torsten Zuberbier and Dr Sophia Neisinger share their live reflections on the 7th Global Allergy and Asthma Excellence Network GUF event, including personal highlights, tips for junior physicians to make meaningful contributions to meetings and details on GUF 2025.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 100 - Urticaria Day 2024 (00:30:01)
Episode 100 – In this special episode, recorded on Urticaria Day (UDAY), Professor Torsten Zuberbier and Dr Carolina Vera welcome CSU patient advocate Kristen Willard, who shares her story of living with urticaria. With live audience participation, this episode also delves into the cause of itch, the impact of urticaria on mental health, and novel treatments.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 99 - How should I treat patients who experience a slow or partial response? (00:22:28)
Professors Torsten Zuberbier and Dave Khan share their experiences and approaches to treating people with refractory CSU, noting the importance of ensuring a correct diagnosis and following guideline recommendations.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 98 - Living with CSU: The patient outlook (00:20:58)
“It stops my daily life as I know it.” Patient advocate with CSU Kristen Willard joins Professor Torsten Zuberbier to reflect on navigating life with CSU, including the impact on quality of life, potential triggers and the uncertainty around the disease.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 97 - Clinical trials in urticaria: Part 2 (00:29:10)
This episode was recorded before 31 July 2024. Professor Marcus Maurer, Dr Carolina Vera Ayala, and Associate Professor Jonny Peter discuss how new therapeutics progress through the development pipeline, noting the “huge amount of data” required on safety before a molecule enters clinical trials. They also shed light on drug repurposing and why children are a “critical group” for inclusion in trials.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 96 - All things acute urticaria: Part 2 (00:29:33)
[This episode was recorded before 31 July 2024.] "Every chronic urticaria starts as acute urticaria, but not every acute urticaria becomes chronic." Associate Professor Dr Andaç Salman and Professor Marcus Maurer discuss causes of acute urticaria, how diagnosis and management can be improved, and UCARE’s research into drivers of “chronification”.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: Acute and chronic urticaria diagnosis and management taking into account their differences; Acute urticaria – GA2LEN UCARE 2023 conference presentation and Project: CHAPEAU – GA2LEN UCARE Network
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 95 - The similarities and differences between urticaria and mastocytosis (00:20:05)
This episode was recorded before July 31, 2024. Professor Marcus Maurer and Dr Sigurd Broesby-Olsen discuss similarities and differences between urticaria and mastocytosis, two mast cell diseases. They then turn their attention to treatment, sharing their thoughts on ‘killing’ mast cells and the development of more targeted and less toxic therapies.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases; Mast cell–targeting therapies in mast cell activation syndromes; and Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 94 - The scientific approach to urticaria: Part 2 (00:25:28)
"We will only be able to cure this disease and treat it well if we know how it works." Back by popular demand, Dr Jörg Scheffel rejoins Professor Marcus Maurer to discuss the importance and intricacies of mast cell research in urticaria.”
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: A novel approach for studying mast cell-driven disorders: Mast cells derived from induced pluripotent stem cells; and Isolation and Culture of Human Skin Mast Cells.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 93 - The use of corticosteroids in urticaria (00:21:34)
Dr Maryam Ali Al-Nesf joins Professor Marcus Maurer to discuss one of the big burdens of chronic urticaria: the "use, or should we say abuse, of cortisone" in chronic spontaneous urticaria.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: Efficacy and safety of systemic corticosteroids for urticaria: A systematic review and meta-analysis of randomized clinical trials; and A patient charter for chronic urticaria.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 100 will be held live on UDAY (1 October 2024, 14:30 CEST). Submit your questions in advance to info@ga2len-ucare.com.
Follow UCARE on Instagram to be notified of more information https://www.instagram.com/ga2len_acare_ucare/.
Episode 92 - Obesity and urticaria (00:27:31)
Professor Christian Vestergaard and Professor Marcus Maurer discuss the link between obesity and urticaria, including how obesity contributes to chronic inflammation and the importance of P4 medicine (preventive, predictive, personalised, participatory) in urticaria treatment.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: High waist circumference rather than high body mass index may be a predictive risk factor for the longer disease duration of chronic spontaneous urticaria; and Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 100 will be held live on UDAY (1 October 2024, 14:30 CEST). Submit your questions in advance to info@ga2len-ucare.com.
Follow UCARE on Instagram to be notified of more information https://www.instagram.com/ga2len_acare_ucare/.
Episode 91 - EAACI 2024 (00:27:32)
Professor Marcus Maurer and Professor Martin Metz reflect on the European Academy of Allergy and Clinical Immunology (EAACI) congress 2024, including novel treatments on the horizon, key takeaways and expectations for future meetings.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Additional resources for this episode: Remibrutinib demonstrates favourable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks; andEuropean Medicines Agency approved indications for omalizumab biosimilar.
Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes!
For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
Episode 100 will be held live on UDAY (1 October 2024, 14:30 CEST). Submit your questions in advance to info@ga2len-ucare.com.
Follow UCARE on Instagram to be notified of more information https://www.instagram.com/ga2len_acare_ucare/.
Side 1 av 3
All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier - Gratis RSS Feed for Norsk Podcast | OpenPodMe | OpenPodMe - Åpen RSS for Norske Podcaster
